ELI LILLY & Co (LLY) vs Merck & Co., Inc. (MRK)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | LLY | MRK |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $65.18B | $65.01B |
| Revenue growth (YoY) | ▲ 44.7% | ▲ 1.3% |
| Net income | $20.64B | $18.25B |
| Gross margin | 83.0% | 74.8% |
| Diluted EPS | $22.95 | $7.28 |
| Insider net (6 mo) | −31.3K sh • 5 sells • 0 buys | −74.8K sh • 9 sells • 0 buys |
| Institutional owners | 51 | 46 |
| Institutional value held | $533.23B | $170.91B |
| Next earnings (est.) | Around Oct 29, 2026 | Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
About Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global health care company operating through two reportable segments, Pharmaceutical and Animal Health, generating total sales of $64.2 billion in 2024, up from $60.1 billion in 2023 and $59.3 billion in 2022. Read more →
Source: SEC EDGAR.